

ANTIBODIES.COM LIMITED
Financial Statements
for the Period from 01 May 2022 to 30 April 2023

ANTIBODIES.COM LIMITED

Financial Statements for the period ending 30 April 2023

CONTENTS	PAGE
Company Information	2
Statement of Financial Position	3
Notes to the Accounts	4

ANTIBODIES.COM LIMITED

Financial Statements for the period ending 30 April 2023

Company Information

Company Details

Company Number 09563058

Registered Office 8 Station Court Station Road
Great Shelford
Cambridge
Cambridgeshire
CB22 5NE

Directors

Directors who held office during the period were:

Sebastian NEWLOVE

Eric Kenelm FORD

Sebastian James NEWLOVE

NEWLOVE, Stewart Anthony, Dr

Graham Cedric PLATTS

ANTIBODIES.COM LIMITED

Financial Statements for the period ending 30 April 2023

Statement of Financial Position

	Notes	2023	2022
		£	£
Fixed Assets			
Intangible assets	5	5,758	5,768
Tangible assets	6	12,075	8,508
Investments	7	2,073	-
Current Assets			
Stocks		87,600	59,017
Debtors due		207,921	80,330
Cash at bank and in hand		496,160	148,488
		<u>791,681</u>	<u>287,835</u>
Creditors			
Amount falling due within one year		(79,200)	(58,499)
Net Current Assets		<u>712,481</u>	<u>229,336</u>
Total Assets less current liabilities		<u>732,387</u>	<u>243,612</u>
Net Assets		<u>732,387</u>	<u>243,612</u>
Capital and Reserves			
Called up Share Capital		599	512
Share Premium Account		850,172	345,272
Retained earnings at end of year		<u>(118,384)</u>	<u>(102,172)</u>
Shareholder funds		<u>732,387</u>	<u>243,612</u>

For the year ending 30/04/2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities.

Approved by the Board on 17 November 2023

S.A. Newlove

Company Registration No. 09563058

ANTIBODIES.COM LIMITED

Financial Statements for the period ending 30 April 2023

Notes to the Accounts

1. Statutory Information

2. Accounting Policies

Basis of preparing the Financial Statements

The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities.

Presentation Currency

The accounts are presented in £ sterling.

ANTIBODIES.COM LIMITED

Financial Statements for the period ending 30 April 2023

Notes to the Accounts

3. Employees

Average number of employees, including directors, during the year was as follows:

2023	5
2022	4

4. Principal Activity

Sales of Reagents to Research Laboratories

ANTIBODIES.COM LIMITED

Financial Statements for the period ending 30 April 2023

Notes to the Accounts

5. Intangible Assets

	Goodwill	Other	Total
Cost	£	£	£
At 01/05/2022	-	6,568	6,568
Additions	-	720	720
Disposals	-	-	-
Revaluations	-	-	-
At 30/04/2023	-	7,288	7,288
Amortisation			
At 01/05/2022	-	800	800
Charge for the Year	-	730	730
On Disposals	-	-	-
Other increases/(decreases)	-	-	-
At end of period	-	1,530	1,530
Net book value			
At 30/04/2023	-	5,758	5,758
At 30/04/2022	-	5,768	5,768

6. Fixed Assets

	Plant and Machinery	Fixtures and Fittings	Total
Cost or valuation	£	£	£
At 01/05/2022	3,589	9,359	12,948
Additions	1,083	7,984	9,067
At 30/04/2023	4,672	17,343	22,015
Depreciation			
At 01/05/2022	1,000	3,440	4,440
Charge for the year	900	4,600	5,500
At 30/04/2023	1,900	8,040	9,940
Net Book Value			
At 30/04/2023	2,772	9,303	12,075
At 30/04/2022	2,589	5,919	8,508

ANTIBODIES.COM LIMITED

Financial Statements for the period ending 30 April 2023

Notes to the Accounts

7. Investments

	Investments in Subsidiaries	Other Investments - Listed	Other Investments -Unlisted	Total
	£	£	£	£
Valuation at 01/05/2022	-	-	-	-
Additions	2,073	-	-	2,073
Disposals	-	-	-	-
Adjustments	-	-	-	-
Valuation at 30/04/2023	2,073	-	-	2,073

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.